Technical Analysis for RNN - Rexahn Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 4.96 2.69% 0.13
RNN closed up 2.69 percent on Friday, May 24, 2019, on 4 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical RNN trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.69%
180 Bearish Setup Bearish Swing Setup 2.69%
Narrow Range Bar Range Contraction 2.69%
Inside Day Range Contraction 2.69%
Wide Bands Range Expansion 2.69%
Oversold Stochastic Weakness 2.69%
Stochastic Buy Signal Bullish -0.40%
Wide Bands Range Expansion -0.40%

Older signals for RNN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system disorders, sexual dysfunction, and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt-1, which has completed a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as is focusing on initiating Phase IIa clinical trials for chemo-resistant solid tumors and hematological malignancies; RX-3117, which has completed an exploratory Phase I clinical study in humans with therapeutic potential in a range of cancers, including colon, lung, and pancreatic cancer; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase and focuses on initiating Phase I clinical trials. The company's pre-clinical pipeline consist of RX-0201-Nano, a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, nano-polymer anticancer. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.
Cancer Cancers Pancreatic Cancer Central Nervous System Disorders Hematological Malignancies Treatment Of Pancreatic Cancer Chemo Protein Kinase B Sexual Dysfunction
Is RNN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.36
52 Week Low 4.71
Average Volume 204,381
200-Day Moving Average 12.0731
50-Day Moving Average 6.0473
20-Day Moving Average 5.4865
10-Day Moving Average 5.007
Average True Range 0.3787
ADX 22.48
+DI 18.0537
-DI 26.8007
Chandelier Exit (Long, 3 ATRs ) 5.4438
Chandelier Exit (Short, 3 ATRs ) 5.8461
Upper Bollinger Band 6.5333
Lower Bollinger Band 4.4397
Percent B (%b) 0.25
BandWidth 38.159118
MACD Line -0.3657
MACD Signal Line -0.3375
MACD Histogram -0.0282
Fundamentals Value
Market Cap 141.15 Million
Num Shares 28.5 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -4.91
Price-to-Sales 0.00
Price-to-Book 3.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.26
Resistance 3 (R3) 5.24 5.11 5.21
Resistance 2 (R2) 5.11 5.03 5.12 5.20
Resistance 1 (R1) 5.03 4.98 5.07 5.06 5.18
Pivot Point 4.91 4.91 4.92 4.92 4.91
Support 1 (S1) 4.83 4.83 4.87 4.86 4.74
Support 2 (S2) 4.70 4.78 4.72 4.72
Support 3 (S3) 4.63 4.70 4.71
Support 4 (S4) 4.66